Towards Healthcare
Biologics Market Size, Shares | 7.6% Growth Rate

Biologics Market Size to Expand USD 845.78 Billion by 2033

The report covers Biologics Market Top Companies and Segments Outlook such as products span across blood and blood products, cellular and gene therapy products, tissue and tissue products, vaccines and others. Indications for their use include oncology, immunology, infectious diseases and other medical conditions. Biologics find application both in diagnosis and treatment. Geographically, the market is distributed across North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. The report offers the value (in USD Billion) for the above segments.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Biologics Market Assessment

  • Overview
  • Global Biologics Market Size Value (US$) and Volume (Billion Tons), by Product (2021 – 2033)
    • Blood and Blood Products
    • Cellular and Gene Therapy Products
    • Tissue and Tissue Products
    • Vaccines
    • Others Types
  • Global Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Oncology
    • Immunology
    • Infectiuos Disease
    • Other Indications
  • Global Biologics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Diagnosis
    • Treatment
  • Global Biologics Market Size Value (US$) and Volume (Billion Tons), by Manufacturing Facility (2021 – 2033)
    • Outsourced
    • In-house
  • Global Biologics Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa

North America Biologics Market Assessment

  • Overview
  • North America Biologics Market Size Value (US$) and Volume (Billion Tons), by Product (2021 – 2033)
    • Blood and Blood Products
    • Cellular and Gene Therapy Products
    • Tissue and Tissue Products
    • Vaccines
    • Others Types
  • North America Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Oncology
    • Immunology
    • Infectiuos Disease
    • Other Indications
  • North America Biologics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Diagnosis
    • Treatment
  • North America Biologics Market Size Value (US$) and Volume (Billion Tons), by Manufacturing Facility (2021 – 2033)
    • Outsourced
    • In-house

Europe Biologics Market Assessment

  • Overview
  • Europe Biologics Market Size Value (US$) and Volume (Billion Tons), by Product (2021 – 2033)
    • Blood and Blood Products
    • Cellular and Gene Therapy Products
    • Tissue and Tissue Products
    • Vaccines
    • Others Types
  • Europe Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Oncology
    • Immunology
    • Infectiuos Disease
    • Other Indications
  • Europe Biologics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Diagnosis
    • Treatment
  • Europe Biologics Market Size Value (US$) and Volume (Billion Tons), by Manufacturing Facility (2021 – 2033)
    • Outsourced
    • In-house

Asia Pacific Biologics Market Assessment

  • Overview
  • Asia Pacific Biologics Market Size Value (US$) and Volume (Billion Tons), by Product (2021 – 2033)
    • Blood and Blood Products
    • Cellular and Gene Therapy Products
    • Tissue and Tissue Products
    • Vaccines
    • Others Types
  • Asia Pacific Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Oncology
    • Immunology
    • Infectiuos Disease
    • Other Indications
  • Asia Pacific Biologics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Diagnosis
    • Treatment
  • Asia Pacific Biologics Market Size Value (US$) and Volume (Billion Tons), by Manufacturing Facility (2021 – 2033)
    • Outsourced
    • In-house

Latin America Biologics Market Assessment

  • Overview
  • Latin America Biologics Market Size Value (US$) and Volume (Billion Tons), by Product (2021 – 2033)
    • Blood and Blood Products
    • Cellular and Gene Therapy Products
    • Tissue and Tissue Products
    • Vaccines
    • Others Types
  • Latin America Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Oncology
    • Immunology
    • Infectiuos Disease
    • Other Indications
  • Latin America Biologics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Diagnosis
    • Treatment
  • Latin America Biologics Market Size Value (US$) and Volume (Billion Tons), by Manufacturing Facility (2021 – 2033)
    • Outsourced
    • In-house

Middle East and Africa Biologics Market Assessment

  • Overview
  • Middle East and Africa Biologics Market Size Value (US$) and Volume (Billion Tons), by Product (2021 – 2033)
    • Blood and Blood Products
    • Cellular and Gene Therapy Products
    • Tissue and Tissue Products
    • Vaccines
    • Others Types
  • Middle East and Africa Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Oncology
    • Immunology
    • Infectiuos Disease
    • Other Indications
  • Middle East and Africa Biologics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Diagnosis
    • Treatment
  • Middle East and Africa Biologics Market Size Value (US$) and Volume (Billion Tons), by Manufacturing Facility (2021 – 2033)
    • Outsourced
    • In-house

Company Profiles

  • Amgen
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Merck & Co.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb
  • Sanofi
  • Bayer AG
  • AstraZeneca
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Eli Lilly and Company

Conclusion & Recommendations

  • Insight Code: 5108
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: February 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

Biosimilar products are biological medicines highly similar to already approved biologic drugs, known as reference or originator biologics. These biosimilars are developed to have efficacy, safety and quality comparable to the original biologic, but different manufacturers produce them. Unlike generic versions of small-molecule drugs, which are identical to the original chemical compounds, biosimilars are not exact copies due to the complexity of biologics.

The monoclonal antibodies (mAbs) segment significantly drives growth in the biologics market. Monoclonal antibodies are biological therapy that has seen substantial innovation and success in various therapeutic areas, including oncology, autoimmune diseases and infectious diseases.

Biologics development involves complex and costly processes, including extensive research, clinical trials, and manufacturing. The high upfront costs can be a barrier for smaller companies and may impact the overall affordability of biologic therapies. While biosimilars present opportunities for cost savings and increased market competition, their adoption can be hindered by factors such as physician and patient preferences, concerns about efficacy and safety, and marketing strategies of originator biologic manufacturers.

Food and Drug Administration, World Health Organization, American Cancer Society, ASCO.gov., National Institute of Biologics, CDSCO.

Warning: include(report-detail-graphs.php): failed to open stream: No such file or directory in /home/thealthcre/public_html/report-toc.php on line 509

Warning: include(): Failed opening 'report-detail-graphs.php' for inclusion (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/thealthcre/public_html/report-toc.php on line 509